1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Beta Pharma, Inc. - Product Pipeline Review - 2015

Beta Pharma, Inc. - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 26 pages

Beta Pharma, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Beta Pharma, Inc. - Product Pipeline Review - 2015’, provides an overview of the Beta Pharma, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beta Pharma, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Beta Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Beta Pharma, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Beta Pharma, Inc.’s pipeline products

Reasons to buy

- Evaluate Beta Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Beta Pharma, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Beta Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Beta Pharma, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beta Pharma, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Beta Pharma, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Beta Pharma, Inc. - Product Pipeline Review - 2015
Table of Contents
Beta Pharma, Inc. Snapshot 4
Beta Pharma, Inc. Overview 4
Key Information 4
Key Facts 4
Beta Pharma, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Beta Pharma, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Beta Pharma, Inc. - Pipeline Products Glance 11
Beta Pharma, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Beta Pharma, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Beta Pharma, Inc. - Drug Profiles 14
icotinib hydrochloride 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
BPI-0403 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
BPI-3119 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
BPI-5143 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
BPI-4039 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Beta Pharma, Inc. - Pipeline Analysis 19
Beta Pharma, Inc. - Pipeline Products by Target 19
Beta Pharma, Inc. - Pipeline Products by Route of Administration 20
Beta Pharma, Inc. - Pipeline Products by Molecule Type 21
Beta Pharma, Inc. - Pipeline Products by Mechanism of Action 22
Beta Pharma, Inc. - Dormant Projects 23
Beta Pharma, Inc. - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 25
Disclaimer 26

List of Tables
Beta Pharma, Inc., Key Information 4
Beta Pharma, Inc., Key Facts 4
Beta Pharma, Inc. - Pipeline by Indication, 2015 6
Beta Pharma, Inc. - Pipeline by Stage of Development, 2015 7
Beta Pharma, Inc. - Monotherapy Products in Pipeline, 2015 8
Beta Pharma, Inc. - Partnered Products in Pipeline, 2015 9
Beta Pharma, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 10
Beta Pharma, Inc. - Phase I, 2015 11
Beta Pharma, Inc. - Preclinical, 2015 12
Beta Pharma, Inc. - Discovery, 2015 13
Beta Pharma, Inc. - Pipeline by Target, 2015 19
Beta Pharma, Inc. - Pipeline by Route of Administration, 2015 20
Beta Pharma, Inc. - Pipeline by Molecule Type, 2015 21
Beta Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015 22
Beta Pharma, Inc. - Dormant Developmental Projects,2015 23
Beta Pharma, Inc., Subsidiaries 24

List of Figures
Beta Pharma, Inc. - Pipeline by Top 10 Indication, 2015 6
Beta Pharma, Inc. - Pipeline by Stage of Development, 2015 7
Beta Pharma, Inc. - Monotherapy Products in Pipeline, 2015 8
Beta Pharma, Inc. - Partnered Products in Pipeline, 2015 9
Beta Pharma, Inc. - Pipeline by Top 10 Target, 2015 19
Beta Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.